natgillin/translations-raw huggingface dataset:
The concomitant use of Victrelis with rifampicin or anticonvulsants (such as phenytoin, phenobarbital or carbamazepine) may significantly reduce the plasma exposure of boceprevir. 
Sočasna uporaba zdravila Victrelis in rifampicina ali antikonvulzivov (kot so fenitoin, fenobarbital ali karbamazepin) lahko pomembno zmanjša plazemsko izpostavljenost boceprevirju.
Boceprevir is eliminated with a mean plasma half-life (t½) of approximately 3.4 hours. 
Boceprevir se izloča s povprečnim plazemskim razpolovnim časom (t1/2) približno 3,4 ure.
Victrelis should be administered with food. 
Zdravilo Victrelis je treba zaužiti s hrano.
Clear polychlorotrifluoroethylene /PVC/aluminium blisters containing 4 hard capsules per blister cavity. 
Pretisni omoti iz prozornega poliklorotrifluoroetilena/PVC/aluminija, ki vsebujejo 4 trde kapsule na jamico pretisnega omota.
If you are not sure, talk to your doctor or pharmacist before taking Victrelis. 
Če ste negotovi, se posvetujte z zdravnikom ali farmacevtom, preden vzamete zdravilo Victrelis.
The frequency of severe or life threatening infections tends to be higher in boceprevir-containing arms than the control arm. 
Pogostnost hudih ali življenjsko nevarnih okužb je malo večja v skupinah, ki prejemajo boceprevir, kot v kontrolni skupini.
After this period, the medicinal product should be disposed. 
Po tem je treba zdravilo zavreči.
Subjects randomized to receive ribavirin dose reduction (N=249) 
Preiskovanci, randomizirani v skupino z zmanjšanim odmerkom ribavirina (N=249)
• medicine used to treat symptoms of an enlarged prostate - doxazosin and tamsulosin 
• zdravili za zdravljenje simptomov povečane prostate - doksazosin in tamsulozin
Do not take Victrelis in combination with peginterferon alfa and ribavirin if you: • are allergic to boceprevir or any of the other ingredients of this medicine (listed in section 6) 
Ne jemljite zdravila Victrelis v kombinaciji s peginterferonom alfa in ribavirinom: • če ste alergični na boceprevir ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
The European Medicines Agency has deferred the obligation to submit the results of studies with Victrelis in one or more subsets of the paediatric population in chronic viral hepatitis C (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila obvezo za predložitev rezultatov študij z zdravilom Victrelis za vse skupine pediatrične populacije s kroničnim virusnim hepatitisom C (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
In rats, boceprevir induced reversible effects on fertility and early embryonic development in female rats at exposures 1.2-fold the human exposure at the recommended therapeutic dose. 
Pri podganah je boceprevir reverzibilno vplival na plodnost in zgodnji embrionalni razvoj pri podganjih samicah pri izpostavljenosti, ki je bila 1,2-krat tolikšna, kot je izpostavljenost človeka pri priporočenem terapevtskem odmerku.
Patients receiving digoxin should be monitored appropriately. 
Bolnike, ki prejemajo digoksin, je treba ustrezno spremljati.
The degree of added value of Victrelis on top of the bitherapy in C/C patients will depend on the likelihood of achieving SVR with the bitherapy only. 
Stopnja dodane vrednosti boceprevirja poleg dvojne terapije pri C/C bolnikih je odvisna od verjetnosti za dosego SVR z dvojno terapijo samo.
If a patient misses a dose and it is 2 or more hours before the next dose is due, the patient should take the missed dose with food and resume the normal dosing schedule. 
Če bolnik pozabi vzeti odmerek in je do naslednjega odmerka 2 uri ali več, mora pozabljeni odmerek vzeti s hrano in nato nadaljevati jemanje po običajnem urniku.
Please see "Possible side effects" for more information. 
Za več informacij, prosimo, glejte poglavje "Možni neželeni učinki".
Use in patients having HCV genotypes other than genotype 1 
Uporaba pri bolnikih s HCV drugih genotipov kot genotipa 1
In a genotype 1a replicon, the IC50 and IC90 values for boceprevir were 900 nM and 1,400 nM, respectively. 
V eni replikacijski enoti genotipa 1a sta bili IC50 za boceprevir 900 nM in IC90 1.400 nM.
As liver function may change during treatment with Victrelis, a close monitoring of International Normalised Ratio (INR) values is recommended in patients treated with vitamin K antagonists. 
Ker se delovanje jeter v času zdravljenja z zdravilom Victrelis lahko spremeni, se pri bolnikih, ki se zdravijo z antagonisti vitamina K, priporoča natančno spremljanje vrednosti mednarodnega normaliziranega razmerja (INR).
In medicine interaction trials conducted with AKR inhibitors diflunisal and ibuprofen, boceprevir exposure did not increase to a clinically significant extent. 
V preskušanjih medsebojnega delovanja, izvedenih z zaviralci AKR diflunisalom in ibuprofenom, se izpostavljenost beceprevirju ni povečala do klinično pomembne vrednosti.
%, (n/N) 73 (80/110) 79 (90/114) EOT %, (n/N) 86 (95/110) 89 (101/114) Relapse 
SVR (n/N) KZ % (n/N) 86 (95/110) 89 (101/114)
• have a condition called ‘autoimmune hepatitis' 
• če imate bolezen, imenovano "avtoimunski hepatitis",
Evaluation of varying combinations of boceprevir and interferon alfa-2b that produced 90% suppression of replicon RNA showed additivity of effect; no evidence of synergy or antagonism was 
Ocena različnih kombinacij boceprevirja in interferona alfa-2b, ki so povzročile 90 % supresijo replikacijske enote RNA, je pokazala aditiven učinek; sinergije ali antagonizma niso ugotovili.
Patients without cirrhosis who are previously untreated or who have failed previous therapy The following dosing recommendations differ for some subgroups from the dosing studied in the Phase 3 trials (see section 5.1). 
Bolniki brez ciroze, ki so predhodno nezdravljeni ali s predhodnim neuspešnim zdravljenjem Naslednja priporočila za odmerjanje se za nekatere podskupine razlikujejo od odmerjanja, ki je bilo preučevano v kliničnih preskušanjih faze 3 (glejte poglavje 5.1).
IL28B rs12979860 was genotyped in 653 of 1,048 (62%) subjects in SPRINT-2 (previously untreated) and 259 of 394 (66%) subjects in RESPOND-2 (previous treatment failure) [see section 5.1 for the clinical trial descriptions]. 
Varianta IL28B rs12979860 je bila genotipizirana pri 653 od 1.048 (62 %) preiskovancev v študiji SPRINT-2 (predhodno nezdravljeni) in pri 259 od 394 (66 %) preiskovancev v študiji RESPOND-2 (predhodno neuspešno zdravljenje) [glejte poglavje 5.1 za opis kliničnih študij].
In 2-year carcinogenicity studies, no carcinogenicity was observed, but there was an increased incidence of hepatocellular adenomas in mice, which was not statistically significant, at systemic exposures 5.7-fold higher than those in humans at the recommended therapeutic dose. 
V 2-letnih študijah kancerogenosti niso opazili kancerogenih učinkov, vendar pa se je pojavnost hepatocelularnih adenomov pri miših povečala ob sistemskih izpostavljenostih, ki so bile 5,7-krat večje kot pri človeku med uporabo priporočenega terapevtskega odmerka, kar pa ni bilo statistično značilno.
Boceprevir has not been studied in patients with decompensated cirrhosis (see section 5.2). 
Boceprevir ni bil raziskan pri bolnikih z dekompenzirano cirozo (glejte poglavje 5.2).
Decreases in neutrophil counts may require dose reduction of peginterferon alfa or discontinuation of therapy. 
Zmanjšanje števila nevtrofilcev lahko zahteva zmanjšanje odmerka peginterferona alfa ali ukinitev zdravljenja.
This is due to liver function changes during treatment with Victrelis. 
Razlog za to so spremembe delovanja jeter pri zdravljenju z zdravilom Victrelis.
If haemoglobin is < 10 g/dL (or < 6.2 mmol/L) management of anaemia may be warranted (see 
Če je hemoglobin < 10 g/dl (oz. < 6,2 mmol/l), je lahko treba urediti anemijo (glejte poglavje 4.8).
Injection-site reactions have not been included since Victrelis is administered orally. 
Reakcije na mestu injiciranja niso bile vključene, ker se zdravilo Victrelis uporablja peroralno.
For additional information on use of Victrelis in patients with advanced liver disease, see section 4.4. 
Za dodatne informacije glede uporabe zdravila Victrelis pri bolnikih z napredovalo boleznijo jeter glejte poglavje 4.4.
Boceprevir has a mean total body clearance (CL/F) of approximately 161 l/hr. 
Boceprevir ima povprečen celotni telesni očistek (CL/F) približno 161 l/uro.
However, the combination therapy of Victrelis, peginterferon alfa and ribavirin may make you feel tired, faint, a sensation of your head spinning, changes in blood pressure, confused or difficulty seeing clearly. 
Vendar pa lahko kombinacija zdravila Victrelis ter peginterferona alfa in ribavirina povzroči utrujenost, omotico, občutek vrtenja v glavi, spremembe krvnega tlaka, zmedenost ali težave z vidom.
Boceprevir was not genotoxic in a battery of in vitro or in vivo assays, including bacterial mutagenicity, human peripheral blood lymphocyte and mouse micronucleus assays. 
Boceprevir ni bil genotoksičen v skupini preizkusov in vitro ali in vivo, vključno s preizkusom mutagenosti pri bakterijah, preizkusom na humanih limfocitih periferne krvi in mikrojedrnim
In a study comparing the use of ribavirin dose reduction and erythropoesis stimulating agents in the management of treatment-emergent anaemia, the use of erythropoesis stimulating agents was associated with an increased risk of thromboembolic events (see section 5.1). 
V študiji, v kateri so primerjali uporabo zmanjšanega odmerka ribavirina in zdravil za stimulacijo eritropoeze za obvladovanje med zdravljenjem nastale anemije, je bila uporaba zdravil za stimulacijo eritropoeze povezana s povečanim tveganjem za nastanek tromboemboličnih zapletov (glejte
No data are available; therefore, the combination of boceprevir with these medicines is not-recommended (see section 4.4). 
Podatkov ni na voljo, zato kombinacija boceprevirja in teh zdravil ni priporočljiva (glejte poglavje 4.4).
No gender-related pharmacokinetic differences in the phase III studies have been observed in adult patients. 
Spol Pri odraslih bolnikih v študijah faze III niso ugotovili s spolom povezanih farmakokinetičnih razlik.
• Store in a refrigerator until expiry. 
• Shranjujte v hladilniku do izteka roka uporabnosti.
• Store in a refrigerator (2C - 8C) until expiry. 
• Shranjujte v hladilniku (2 C - 8 C) do izteka roka uporabnosti.
Boceprevir/metabolites are excreted in rat milk (see section 5.3). 
Boceprevir/presnovki se izločajo v mleku podgan (glejte poglavje 5.3).
Male patients or their female partners must use an effective contraceptive during treatment and for 7 months after treatment has been concluded. 
Moški bolniki in njihove partnerke morajo uporabljati učinkovito kontracepcijo med zdravljenjem in še 7 mesecev po zaključku
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: 
Za vse dodatne informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za
Heart or circulation: abnormal or rapid heart rate; heart disease caused by poor blood flow in 
Srce in obtočila: nenormalno ali hitro bitje srca, bolezen srca zaradi slabega pretoka krvi skozi
• antimicrobial medicine - pentamidine 
• protimikrobna zdravila - pentamidin
Population pharmacokinetic analysis of Victrelis indicated that race had no apparent effect on exposure. 
Populacijska farmakokinetična analiza zdravila Victrelis je pokazala, da rasa nima nobenega opaznega vpliva na izpostavljenost.
In both studies, the addition of Victrelis to the current standard of care (peginterferon alfa and ribavirin) significantly increased sustained virologic response (SVR) rates compared to the current standard of care alone. 
V obeh študijah je dodatek zdravila Victrelis trenutnemu standardnemu zdravljenju (s peginterferonom alfa in z ribavirinom) značilno povečal deleže trajnega virološkega odziva (SVR) v primerjavi s samim trenutnim standardnim zdravljenjem.
Use in patients with rare hereditary disorders 
Uporaba pri bolnikih z redkimi dednimi motnjami
Each capsule contains 56 mg of lactose monohydrate. 
Pomožna snov z znanim učinkom Ena kapsula vsebuje 56 mg laktoze monohidrata.
Co-administration of Victrelis with an oral contraceptive containing ethinyl estradiol and at least 1 mg of norethindrone is unlikely to alter the contraceptive effectiveness. 
Malo verjetno je, da bi sočasna uporaba zdravila Victrelis s peroralnim kontraceptivom, ki vsebuje etinilestradiol in vsaj 1 mg noretindrona, spremenila učinkovitost kontracepcije.
It is possible that boceprevir is excreted in human milk. 
Mogoče je, da se boceprevir izloča v materino mleko.
Mean age of subjects randomized was 52.7 years. 
Povprečna starost randomiziranih preiskovancev je bila 52,7 let.
If such reaction occurs, combination therapy should be discontinued and appropriate medical therapy immediately instituted 
Če se takšna reakcija pojavi, je treba kombinirano zdravljenje prekiniti in nemudoma začeti z ustrezno terapijo (glejte poglavji 4.3 in
Croscarmellose sodium Pre-gelatinized starch Magnesium stearate 
premreženi natrijev karmelozat predgelirani škrob magnezijev stearat
Based on results of clinical studies, Victrelis must not be used alone due to the high probability of increased resistance without combination anti-HCV therapies (see section 5.1). 
Na podlagi izsledkov kliničnih študij se zdravila Victrelis ne sme uporabljati samega, ker brez kombinirane uporabe zdravil za hepatitis C obstaja velika verjetnost povečanja odpornosti (glejte poglavje 5.1).
Given the incremental risk of adverse events with Victrelis (anaemia notably); in case the patient cannot tolerate the treatment, consideration could be given to pursue with 12 weeks of bitherapy for the final 12 weeks of treatment instead of tritherapy (see sections 4.8 and 5.1). 
Glede na povečano tveganje za neželene učinke pri zdravilu Victrelis (najopazneje anemije) lahko po lastni presoji, če bolnik ne prenaša zdravljenja, zadnjih 12 tednov zdravljenja namesto trojnega zdravljenja uporabite dvojno zdravljenje (glejte poglavji 4.8 in 5.1).
Population pharmacokinetic analysis of Victrelis indicated that age had no apparent effect on exposure. 
Populacijska farmakokinetična analiza zdravila Victrelis je pokazala, da starost nima nobenega opaznega vpliva na izpostavljenost.
• HIV protease inhibitors - atazanavir, darunavir, lopinavir, ritonavir 
• zaviralce HIV proteaze - atazanavir, darunavir, lopinavir, ritonavir
Treatment with Victrelis should be initiated and monitored by a physician experienced in the 
Zdravljenje z zdravilom Victrelis mora uvesti in spremljati zdravnik z izkušnjami z zdravljenjem
Indeed, serum progesterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels indicated that ovulation was suppressed during coadministration of norethindrone 1 mg/ethinyl estradiol 0.035 mg with Victrelis (see section 4.6). 
Pravzaprav so serumske koncentracije progesterona, luteinizirajočega hormona (LH) in folikle stimulirajočega hormona (FSH) pokazale, da je bila med sočasno uporabo noretindrona 1 mg/ etinilestradiola 0,035 mg in zdravila Victrelis ovulacija zavrta (glejte poglavje 4.6).
Victrelis contains lactose (a type of sugar). 
Zdravilo Victrelis vsebuje laktozo (vrsto sladkorja).
No human data on the effect of Victrelis on fertility are available. 
Podatkov o vplivu zdravila Victrelis na plodnost pri človeku ni na voljo.
Boceprevir concentrations are not likely to be affected by maraviroc co-administration (based on elimination pathway of boceprevir). 
Malo verjetno je, da sočasna uporaba maraviroka vpliva na koncentracije boceprevirja (glede na pot izločanja boceprevirja).
These blood tests are done for a number of reasons: 
Zdravnik vas bo napotil na redne preiskave krvi, ki jih je treba opraviti iz več razlogov:
RAVs were detected in 8% of patients at baseline by population sequencing. 
RAV so bile s populacijskim sekveniranjem na začetku zdravljenja odkrite pri 8 % bolnikov.
Of 314 treatment-naïve and previously treated subjects who did not achieve SVR from Phase 2/3 studies (P03523, P03659, P05216, and P05101) in whom boceprevir-resistant variants had emerged during treatment, 73% (228/314) of subjects no longer had any RAVs detected at the boceprevir-resistance associated loci by population sequencing within 3 years post-therapy. 
Od 314 predhodno nezdravljenih in predhodno zdravljenih preiskovancev, ki v študijah faze II/III (P03523, P03659, P05216 in P05101) niso dosegli SVR in pri katerih so se med zdravljenjem pojavile na boceprevir odporne variante virusa, pri 73 % (228/314) preiskovancev s populacijskim sekveniranjem v roku 3 let po zdravljenju niso več zaznali nobenih RAV na lokusih, povezanih z odpornostjo na boceprevir.
Pack sizes: carton of 84 hard capsules and multipack containing 336 (4 packs of 84) hard capsules. 
Velikost pakiranja: škatla s 84 trdimi kapsulami in multi pakiranje, ki vsebuje 336 (4 pakiranja po 84)
Studies in vitro indicate that boceprevir primarily undergoes metabolism through the aldoketoreductase (AKR)-mediated pathway to ketone-reduced metabolites that are inactive against HCV. 
Študije in vitro kažejo, da se boceprevir primarno presnovi po aldo-ketoreduktazni (AKR) poti v ketonske reducirane presnovke, ki so proti HCV neaktivni.
Victrelis may be used in adults who are previously untreated for HCV infection or who have previously used medicines called ‘interferons' and ‘pegylated interferons'. 
Zdravilo Victrelis se lahko uporablja pri odraslih, ki zaradi okužbe s HCV še niso bili zdravljeni, in pri odraslih, ki so prej že prejemali zdravila, imenovana "interferoni" in "pegilirani interferoni".
Victrelis does not affect your ability to drive or use tools or machines. 
Zdravilo Victrelis ne vpliva na sposobnost vožnje in upravljanja strojev.
The data available (see section 5.3) warrant caution in patients at risk of QT prolongation (long 
Razpoložljivi podatki (glejte poglavje 5.3) zahtevajo previdnost pri bolnikih s tveganjem za podaljšanje QT intervala (prirojeni daljši QT interval, hipokaliemija).
Each hard capsule contains 200 mg boceprevir. 
Ena trda kapsula vsebuje 200 mg boceprevirja.
• hormonal replacement therapy - oestrogen-based medicines 
• hormonsko nadomestno zdravljenje - estrogenska zdravila
The combination of boceprevir with these medicines is not recommended (see section 4.4). 
Kombinacija boceprevirja s temi zdravili ni priporočljiva (glejte poglavje 4.4).
The mean decreases in haemoglobin values from baseline were larger in previously treated patients compared to patients who had never received prior therapy. 
Povprečno zmanjšanje vrednosti hemoglobina od izhodišča je bilo večje pri predhodno zdravljenih bolnikih kot pri predhodno še nezdravljenih bolnikih.
The SVR rate was 62.5% (40/64) in subjects treated with Victrelis in combination with PR and 29.4% (10/34) in subjects treated with PR alone (see Table 6). 
Delež SVR je znašal 62,5 % (40/64) pri preiskovancih, ki so bili zdravljeni z zdravilom Victrelis v kombinaciji s PR, in 29,4 % (10/34) pri preiskovancih, ki so bili zdravljeni samo s PR (glejte
The safety profile of Victrelis in HCV/HIV-1 co-infected patients (n=64) was overall similar to the safety profile in mono-infected HCV patients. 
Varnostni profil zdravila Victrelis je bil pri bolnikih, sočasno okuženih s HCV/HIV (n=64), na splošno podoben varnostnemu profilu zdravila pri bolnikih, okuženih samo s HCV.
• have low blood potassium (hypokalaemia) 
• če imate nizko koncentracijo kalija v krvi (hipokaliemijo).
Concomitant administration of Victrelis and quetiapine may increase plasma concentrations of quetiapine leading to quetiapine-related toxicity, including coma. 
Pri sočasni uporabi zdravila Victrelis in kvetiapina se lahko povečajo plazemske koncentracije kvetiapina, ki vodijo do s kvetiapinom povezane toksičnosti, vključno s komo.
The median time for all RAVs to become undetectable was 1.04 years for genotype 1b. 
Mediani čas, da so nezaznavne postale vse RAV, je bil za genotip 1b 1,04 let.
In comparison, 79% (66/84) of genotype 1b subjects no longer had any RAVs detected at the boceprevir-resistance associated loci by population sequencing. 
Za primerjavo, pri 79 % (66/84) preiskovancev, okuženih z genotipom 1b, s populacijskim sekveniranjem ni bilo zaznavnih nobenih RAV na lokusih, povezanih z odpornostjo na boceprevir.
In repeat-dose toxicity studies boceprevir showed testicular degeneration in rats at systemic exposures lower than those in humans at the recommended human therapeutic dose. 
V študijah toksičnosti ponavljajočih se odmerkov boceprevirja so pri podganah ugotovili degeneracijo mod pri sistemskih izpostavljenostih, ki so bile manjše od tistih pri človeku med uporabo priporočenega terapevtskega odmerka za človeka.
Victrelis 200 mg hard capsules boceprevir 
Victrelis 200 mg trde kapsule boceprevir
Victrelis 200 mg hard capsules 
Victrelis 200 mg trde kapsule
This co-administration might be considered on a case by case basis if deemed necessary, in patients with suppressed HIV viral loads and with HIV viral strain without any suspected resistance to the HIV regimen. 
Takšna sočasna uporaba lahko pride v poštev pri posameznih bolnikih, ki imajo zmanjšano virusno breme virusa HIV in so okuženi s sevom virusa HIV, za katerega ni nobenega dvoma o rezistenci na režim zdravljenja HIV.
The SVR rates for those who received at least one dose of Victrelis (i.e. excluding patients who discontinued during PR lead-in) are 41% for null responders, 67% for partial responders and 96% for relapsers. 
Pri tistih, ki so prejeli vsaj en odmerek zdravila Victrelis (tj. brez bolnikov, ki so izstopili med uvajalnim obdobjem s PR), so bili deleži SVR 41 % pri popolnoma neodzivnih bolnikih, 67 % pri delno odzivnih bolnikih in 96 % pri
Adverse reactions are listed by System Organ Class (see Table 3). 
Neželeni učinki so navedeni po organskih sistemih (glejte preglednico 3).
All patients in this treatment arm were limited to 32 weeks of Victrelis. 
Zdravljenje z zdravilom Victrelis je bilo pri vseh bolnikih v tej skupini omejeno na 32 tednov.
1 plasma HCV-RNA at Follow-up Week (FW) 24. 
1 plazemska HCV-RNA v 24. tednu spremljanja (TS).
The most frequently reported adverse reactions were fatigue, anaemia (see section 4.4), nausea, 
Neželeni učinki, o katerih so poročali najpogosteje, so bili: utrujenost, anemija (glejte poglavje 4.4),
• CYP3A4 inducer medicines (such as antibiotic medicine - rifampicin, and anticonvulsant medicines - carbamazepine, phenobarbital, phenytoin) 
• zdravila, ki inducirajo CYP3A4 (kot so antibiotiki - rifampicin in antikonvulzivi karbamazepin, fenobarbital, fenitoin)
• difficulty breathing or swallowing, wheezing, hives, itching, swelling of your face, eyes, lips, 
• težave z dihanjem ali požiranjem, piskajoče dihanje, koprivnico, srbenje, otekanje obraza, oči,
The race distribution of subjects was as follows: 77% White, 19% Black, and 4% others. 
Porazdelitev preiskovancev po rasah je bila naslednja: 77 % belcev, 19 % črncev in 4 % ostalih.
Alternative contraceptives should be considered (see section 4.5). 
Razmisliti je treba o uporabi drugih kontraceptivov (glejte poglavje 4.5).
In poorly interferon responsive patients (defined as < 1-log10 decline in HCV-RNA at TW 4) the use of triple therapy should be considered on a case by case basis, as the likelihood of achieving sustained virologic response (SVR) with triple therapy is lower in these patients (see section 5.1). 
Pri bolnikih, slabo odzivnih na interferon (opredeljenih kot tisti, ki so imeli 4. teden zdravljenja < 1-log10 zmanjšanje HCV-RNA), je treba o zdravljenju s tremi zdravili razmisliti pri vsakem posameznem bolniku, ker je verjetnost za dosego trajnega virološkega odziva (SVRSustained Virologic Response) s tremi zdravili pri teh bolnikih manjša (glejte poglavje 5.1).
If you have any further questions on the use of this medicine, ask your doctor or pharmacist because 
Če imate dodatna vprašanja o uporabi tega zdravila, se posvetujte z zdravnikom ali farmacevtom, ker vaše zdravljenje morda ne bo učinkovito.